<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Elixirgen Therapeutics</title>
    <link>https://www.biospace.com/employer/3076392/elixirgen-therapeutics</link>
    <description>Elixirgen Therapeutics</description>
    <language>en-US</language>
    <lastBuildDate>Thu, 04 Jun 2020 13:16:05 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/3076392/elixirgen-therapeutics.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure</title>
      <link>https://www.biospace.com/fda-approves-elixirgen-therapeutics-ind-application-for-therapy-for-telomere-biology-disorders-with-bone-marrow-failure</link>
      <description>Elixirgen Therapeutics, Inc., a Baltimore -based biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines, received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for its lead candidate, EXG34217, wa</description>
      <pubDate>Thu, 04 Jun 2020 13:16:05 GMT</pubDate>
      <guid>https://www.biospace.com/fda-approves-elixirgen-therapeutics-ind-application-for-therapy-for-telomere-biology-disorders-with-bone-marrow-failure</guid>
    </item>
    <item>
      <title>Elixirgen Therapeutics Concludes pre-IND Meeting with FDA for its COVID-19 Vaccine Candidate EXG-5003</title>
      <link>https://www.biospace.com/elixirgen-therapeutics-concludes-pre-ind-meeting-with-fda-for-its-covid-19-vaccine-candidate-exg-5003</link>
      <description>Elixirgen Therapeutics, Inc., a Baltimore -based biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines, announced that it concluded on May 18 its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the company's C</description>
      <pubDate>Thu, 04 Jun 2020 13:26:06 GMT</pubDate>
      <guid>https://www.biospace.com/elixirgen-therapeutics-concludes-pre-ind-meeting-with-fda-for-its-covid-19-vaccine-candidate-exg-5003</guid>
    </item>
    <item>
      <title>Elixirgen Therapeutics planning to begin Phase I/II Clinical Trials of its COVID-19 Vaccine Candidate EXG-5003 at Fujita Health University</title>
      <link>https://www.biospace.com/elixirgen-therapeutics-planning-to-begin-phase-i-ii-clinical-trials-of-its-covid-19-vaccine-candidate-exg-5003-at-fujita-health-university</link>
      <description>Elixirgen Therapeutics, Inc., a Baltimore -based biotechnology company focused on the discovery, development and commercialization of therapies for genetic diseases and vaccines, announced that Fujita Health University has received a contract from the Japan Agency for Medical Research and Development (AMED) to initiate Phase I/II cli</description>
      <pubDate>Tue, 01 Sep 2020 12:46:06 GMT</pubDate>
      <guid>https://www.biospace.com/elixirgen-therapeutics-planning-to-begin-phase-i-ii-clinical-trials-of-its-covid-19-vaccine-candidate-exg-5003-at-fujita-health-university</guid>
    </item>
    <item>
      <title>Elixirgen Therapeutics Announces Dosing of First and Second Participants in its COVID-19 Vaccine Phase 1/2 Clinical Trial at Fujita Health University</title>
      <link>https://www.biospace.com/elixirgen-therapeutics-announces-dosing-of-first-and-second-participants-in-its-covid-19-vaccine-phase-1-2-clinical-trial-at-fujita-health-university</link>
      <description>Elixirgen Therapeutics, Inc., a Baltimore -based biotechnology company focused on the discovery and development of therapies for genetic diseases and vaccines, today announced the dosing of the first and second participants in its COVID-19 vaccine Phase 1/2 Clinical Trial in Japan .</description>
      <pubDate>Tue, 25 May 2021 12:36:11 GMT</pubDate>
      <guid>https://www.biospace.com/elixirgen-therapeutics-announces-dosing-of-first-and-second-participants-in-its-covid-19-vaccine-phase-1-2-clinical-trial-at-fujita-health-university</guid>
    </item>
    <item>
      <title>Elixirgen Therapeutics Announces Licensing Agreement for Its Novel COVID-19 Vaccine</title>
      <link>https://www.biospace.com/elixirgen-therapeutics-announces-licensing-agreement-for-its-novel-covid-19-vaccine</link>
      <description>Elixirgen Therapeutics, Inc. today announced it has entered into an exclusive licensing agreement with a global pharmaceutical company (currently undisclosed) for the rights to commercialize its self-replica</description>
      <pubDate>Fri, 08 Oct 2021 12:36:09 GMT</pubDate>
      <guid>https://www.biospace.com/elixirgen-therapeutics-announces-licensing-agreement-for-its-novel-covid-19-vaccine</guid>
    </item>
    <item>
      <title>Elixirgen Therapeutics Partners with Taisho Pharmaceutical on Therapeutics for Aging-Associated Diseases</title>
      <link>https://www.biospace.com/elixirgen-therapeutics-partners-with-taisho-pharmaceutical-on-therapeutics-for-aging-associated-diseases</link>
      <description>Elixirgen Therapeutics, Inc. announced that it has entered into an exclusive three-year research collaboration agreement with Taisho Pharmaceutical Co., Ltd.</description>
      <pubDate>Mon, 07 Mar 2022 10:36:08 GMT</pubDate>
      <guid>https://www.biospace.com/elixirgen-therapeutics-partners-with-taisho-pharmaceutical-on-therapeutics-for-aging-associated-diseases</guid>
    </item>
    <item>
      <title>Elixirgen Therapeutics to Present New Data Showing Successful Ex Vivo Telomere Elongation with EXG-34217 in a Phase 1/2 Clinical Trial at the 64th ASH Annual Meeting</title>
      <link>https://www.biospace.com/elixirgen-therapeutics-to-present-new-data-showing-successful-ex-vivo-telomere-elongation-with-exg-34217-in-a-phase-1-2-clinical-trial-at-the-64th-ash-annual-meeting</link>
      <description>Elixirgen Therapeutics, Inc. today announced an oral presentation of new data showing successful ex vivo telomere elongation with lead asset, EXG-34217 (autologous CD34+ hematopoietic stem cells that have been treated with EXG-001), at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022 in New Orleans, Louisiana.</description>
      <pubDate>Mon, 07 Nov 2022 13:06:15 GMT</pubDate>
      <guid>https://www.biospace.com/elixirgen-therapeutics-to-present-new-data-showing-successful-ex-vivo-telomere-elongation-with-exg-34217-in-a-phase-1-2-clinical-trial-at-the-64th-ash-annual-meeting</guid>
    </item>
    <item>
      <title>Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting</title>
      <link>https://www.biospace.com/elixirgen-therapeutics-presents-new-clinical-data-demonstrating-ex-vivo-telomere-elongation-with-exg-34217-in-dyskeratosis-congenita-at-the-64th-ash-annual-meeting</link>
      <description>Elixirgen Therapeutics, Inc. today announced new data from a Phase 1/2 trial (NCT04211714) showing successful ex vivo telomere elongation with lead asset, EXG-34217 (autologous CD34+ hematopoietic stem cells that have been treated ex vivo with EXG-001), in a patient</description>
      <pubDate>Mon, 12 Dec 2022 16:36:04 GMT</pubDate>
      <guid>https://www.biospace.com/elixirgen-therapeutics-presents-new-clinical-data-demonstrating-ex-vivo-telomere-elongation-with-exg-34217-in-dyskeratosis-congenita-at-the-64th-ash-annual-meeting</guid>
    </item>
    <item>
      <title>Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors</title>
      <link>https://www.biospace.com/elixirgen-therapeutics-appoints-jeffrey-l-cleland-ph-d-to-board-of-directors</link>
      <description>Elixirgen Therapeutics, Inc. today announced the appointment of Jeffrey L. Cleland, Ph.D., to the Board of Directors to support the advancement of its technology in developing therapies for a broad spectrum of diseases including rare diseases, aging-related disorders and cancer.</description>
      <pubDate>Wed, 21 Dec 2022 13:06:12 GMT</pubDate>
      <guid>https://www.biospace.com/elixirgen-therapeutics-appoints-jeffrey-l-cleland-ph-d-to-board-of-directors</guid>
    </item>
    <item>
      <title>Elixirgen Therapeutics to Attend the 2023 Biotech Showcase Conference</title>
      <link>https://www.biospace.com/elixirgen-therapeutics-to-attend-the-2023-biotech-showcase-conference</link>
      <description>Elixirgen Therapeutics, Inc. announced that members of the management team will be attending the Biotech Showcase Conference taking place January 9-11, 2023 in San Francisco, California.</description>
      <pubDate>Wed, 04 Jan 2023 13:06:07 GMT</pubDate>
      <guid>https://www.biospace.com/elixirgen-therapeutics-to-attend-the-2023-biotech-showcase-conference</guid>
    </item>
  </channel>
</rss>
